JERUSALEM - Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of an authorized generic of Estrace1 Cream (estradiol vaginal cream, USP, 0.01%), in the U.S.
Estradiol vaginal cream, USP, 0.01%, is indicated in the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. This launch is an important addition to Teva's generic women's health portfolio and our growing line of menopause treatments.
With nearly 600 generic
RelSci News & Alerts gets you: